| |
Success or failure of a therapeutic program will depend on the understanding of the market and ability to develop an effective commercial strategy. Download our checklist to gain these insights and learn how Premier Consulting can evaluate the market and maximize the potential of your program throughout the development lifecycle. 
|
|
Today’s Big NewsJun 3, 2024 |
|
September 30- October 1, 2024| Boston, MA The Fierce New Product Planning Summit is the only conference focused on how life science professionals make informed, value-based, data-driven decisions about pipeline products. Experts gather annually to discuss resource utilization and key questions for commercial success. Stay Updated! 
|
|
| By Gabrielle Masson As Keytruda’s 2028 patent cliff looms, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. One of those prongs is improving immune responses, a pillar that stars Moderna-shared cancer vaccine mRNA-4157. |
|
|
|
By Gabrielle Masson As zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing long-term phase 2b data in advanced biliary tract cancer for the HER2-targeted bispecific antibody. The data include the first overall survival (OS) findings from the study, with zanidatamab demonstrating a median OS of 15.5 months compared to the typical six to nine months prognosis for patients receiving chemotherapy after first-line therapy. |
By Annalee Armstrong The future of hereditary angiodema treatment seems to be coming down to how many shots it takes to reduce attacks. Gene editing biotech Intellia Therapeutics is the latest to reveal updated data for its candidate, showing that a single dose of NTLA-2002 provided a durable reduction in the swelling attacks that define the disease. |
Sponsored by Altasciences Discover the increasing body of evidence that supports the use of miniature swine as a viable non-rodent option for nonclinical studies. |
By Gabrielle Masson While 2022 offered quite a few R&D leadership shake-ups, 2023 proved much calmer, with one whopping standout—a $20 million payout for Johnson & Johnson’s new head of pharma R&D. |
By Annalee Armstrong Arrowhead Pharmaceuticals’ RNA interference therapeutic lowered triglycerides in patients with a rare metabolic disease that prevents the body from breaking down fats during a phase 3 trial. |
By Annalee Armstrong Pharmas have a record $1 trillion to deploy on new innovative deals. All they need is for the Federal Reserve to lower rates, according to a new report from Ernst & Young. |
By Annalee Armstrong Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is back with a new cut showing 6% weight loss in a phase 2a study. |
By Conor Hale Purple Biotech hopes its lead asset against metastatic pancreatic cancer will one day show its true colors as a potential first-in-class drug in a larger study—but, for now, it has preliminary, midstage trial results demonstrating measurable gains in overall survival. |
By Nick Paul Taylor Eli Lilly is splicing another asset onto its neurodegenerative disease pipeline, paying QurAlis $45 million for rights to a preclinical treatment for amyotrophic lateral sclerosis and frontotemporal dementia. |
By Annalee Armstrong Rapport Therapeutics is talking up a $122 million IPO, the first in a return to public market interest since an earlier rush this year. |
By Helen Floersh Trial software provider ConcertAI is partnering with Nvidia to develop new clinical simulations that inform future AI products for clinical trials, the company announced May 31 at the American Society of Cancer Oncology’s annual meeting. |
By Angus Liu After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression of the protein biomarker. |
By Conor Hale The startup said it has claimed the world record for the number of electrodes used to detect a person’s brain activity. |
By Angus Liu When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion. |
By Zoey Becker The Inflation Reduction Act's price negotiation measures stand to cut down drug candidates before they can "grow roots" later in development, Eli Lilly CEO David Ricks said during a panel discussion. |
By Noah Tong UnitedHealth gave an overview of areas in which the insurer can improve upon, how Medicaid redeterminations will affect the company and thoughts on OptumRx. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Emma Beavins from Fierce Healthcare interviews CVS Health Chief Medical Officer Sree Chaguturu, M.D., to dive into the topic of telehealth and its role in a comprehensive approach to healthcare. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself. Save $200 when you register today! 
|
|
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
